{"id":4407,"date":"2026-11-18T13:10:52","date_gmt":"2026-11-18T13:10:52","guid":{"rendered":"https:\/\/drsoniafawad.com\/?p=4407"},"modified":"2026-11-18T13:10:52","modified_gmt":"2026-11-18T13:10:52","slug":"universal-germline-genetic-testing-in-cancer-is-right-move","status":"publish","type":"post","link":"https:\/\/drsoniafawad.com\/?p=4407","title":{"rendered":"Universal germline genetic testing in cancer is \u2018right move\u2019"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div data-component=\"ArticleContent\">\n<div class=\"article__below-title\">\n<div class=\" article__posted-date\">\n<p>November 18, 2026<\/p>\n<p>4 min read<\/p>\n<\/p><\/div>\n<div class=\"mobile-trust-box\">\n<div class=\"row\">\n<div class=\"col-12 col-md-5 d-xl-none\">\n<div class=\"trust-box\">\n<div class=\"trust-box-logo d-none d-md-block\">\n            <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hot.svg?la=en&amp;h=24&amp;w=141&amp;hash=2F86D471C8514C0E334E329AA799E8B4\" class=\"logo-img\" height=\"24\" alt=\"hemonc today logo\" width=\"141\"\/>\n          <\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div class=\"col-12 col-md-6 offset-md-1 offset-xl-0 col-xl-12\">\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n  <hidden data-setting-item=\"d265901d-6d37-49c7-a8f6-c7bf19a02509\"\/><br \/>\n  <hidden data-crm-source=\"Subspecialty Topic Alert\"\/><\/p>\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p>&#13;<br \/>\n      <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\">&#13;<br \/>\n        <i class=\"fas fa-plus-circle\"\/>&#13;<br \/>\n        Add topic to email alerts&#13;<br \/>\n      <\/span>&#13;\n    <\/p>\n<div class=\"email-alert-inner collapse u1ad81e56d32445208b911701f5d8da41\">\n<div class=\"email-alert-dialogue\">\n<p>&#13;<br \/>\n          Receive an email when new articles are posted on <span data-content=\"topic-title\"\/>&#13;\n        <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\">\n          Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"\/>.<\/p><\/div>\n<\/p><\/div>\n<p>      <button type=\"button\" class=\"btn btn-primary\" data-loading-text=\"Loading &lt;i class=\" fa=\"\" fa-spinner=\"\" fa-spin=\"\">&#8220;&#13;<br \/>\n              data-action=&#8221;subscribe&#8221;&gt;&#13;<br \/>\n        Subscribe&#13;<br \/>\n      <\/button>\n    <\/div>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\">    <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20261116\/mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong>  <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\n<h2>Key takeaways:<\/h2>\n<ul>\n<li>A common age cutoff for germline genetic testing of solid tumors would have missed nearly three-quarters of people with pathogenic variants.<\/li>\n<li>The findings support universal testing for people with cancer.<\/li>\n<\/ul>\n<p>Use of a commonly used age-based cutoff for genetic testing among individuals with solid tumors resulted in a considerable proportion of inherited gene variants going undetected, according to study findings.<\/p>\n<p>An analysis of nearly 40,000 people with a variety of cancer types showed restricting germline genetic sequencing to those aged younger than 50 years would have missed nearly three-quarters of individuals who harbored pathogenic variants.<\/p>\n<figure class=\"figure article__og-image\">&#13;\n    <picture>&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/misc\/infographics\/hot-infographics\/2026\/11_november\/hot1026stadler_graphic_01.webp?w=476\" media=\"(max-width: 768px)\">&#13;<source srcset=\"https:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/misc\/infographics\/hot-infographics\/2026\/11_november\/hot1026stadler_graphic_01.webp?w=800\" media=\"(max-width: 992px)\">&#13;<source srcset=\"https:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/misc\/infographics\/hot-infographics\/2026\/11_november\/hot1026stadler_graphic_01.webp?w=595\" media=\"(max-width: 1200px)\">&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/misc\/infographics\/hot-infographics\/2026\/11_november\/hot1026stadler_graphic_01.webp?w=476\" media=\"(min-width: 1200px)\">&#13;<source srcset=\"https:\/\/www.healio.comhttps:\/\/www.healio.comhttps:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/misc\/infographics\/hot-infographics\/2026\/11_november\/hot1026stadler_graphic_01.webp?w=476\">&#13;<br \/>\n&#13;<br \/>\n      <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/misc\/infographics\/hot-infographics\/2026\/11_november\/hot1026stadler_graphic_01.jpg?w=800\" alt=\"A 'missed oppurtunity' IG\" class=\"figure-img img-fluid\" width=\"800\"\/>&#13;<br \/>\n    <\/source><\/source><\/source><\/source><\/source><\/picture>&#13;<figcaption class=\"figure-caption\">&#13;<br \/>\n      Data derived from Stadler ZK, et al. <i>Cancer Discov<\/i>. 2026;doi:10.1158\/2159-8290.CD-26-0971.&#13;<br \/>\n    <\/figcaption>&#13;<br \/>\n  <\/figure>\n<p>This equates to a \u201cmissed opportunity\u201d to obtain valuable information that could have profound implications for patients and their family members, according to lead author <b>Zsofia K. Stadler, MD,<\/b> chief of the clinical genetics service and gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center.<\/p>\n<div class=\"mug left\"><img decoding=\"async\" alt=\"Zsofia K. Stadler, MD\" style=\" height:106px; width:80px\" src=\"https:\/\/www.healio.com\/~\/media\/slack-news\/hemonc\/mugs\/s\/stadler_zsofia_2026_.jpg\"\/><\/p>\n<p><strong><b>Zsofia K. Stadler<\/b><\/strong><\/p>\n<\/div>\n<p>\u201cI have always thought that we should be moving toward universal testing for patients with cancer,\u201d Stadler told Healio. \u201cThese findings prove to us that this is the right move and should be the next step.\u201d<\/p>\n<h2>\u2018Somewhat arbitrary\u2019<\/h2>\n<p>Prior research showed early-onset cancers tend to be more enriched for inherited genetic alterations.<\/p>\n<p>People with inherited genetic conditions linked to higher lifetime cancer risk \u2014 such as Lynch syndrome or hereditary breast ovarian cancer syndrome \u2014 also tend to be diagnosed at younger ages.<\/p>\n<p>Consequently, when genetic testing started \u201cin earnest\u201d about 25 years ago, age became part of the criteria to identify the population likely to derive the most benefit, Stadler said.<\/p>\n<p>\u201cOver the years, the pool of individuals eligible for testing for cancer risk genes has expanded tremendously, but criteria still vary by cancer type,\u201d she said.<\/p>\n<p>For example, genetic testing is recommended for everyone with ovarian cancer or <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20260716\/vaccine-designed-to-intercept-pancreatic-cancer-induces-durable-responses\" id=\"rId12\" target=\"_blank\">pancreatic cancer<\/a>. In other malignancies, testing decisions differ by age, family history, ancestry or tumor phenotype.<\/p>\n<p>Stadler and colleagues aimed to investigate whether an age 50 cutoff \u2014 which she described as a commonly used \u201cgatekeeper\u201d for genetic testing \u2014 remains relevant across cancer types, including those that typically present at older ages.<\/p>\n<p>The researchers performed germline sequencing on 39,184 unselected individuals with one of 32 solid tumor types, using the MSK-IMPACT assay to screen for 94 germline pathogenic variants.<\/p>\n<p>Investigators determined mean age at diagnosis for each cancer type, then used standard deviations to stratify people with each malignancy into three groups based on age at onset (average, early or late).<\/p>\n<p>One in six (16.3%) patients harbored at least one germline pathogenic variant.<\/p>\n<p>Results showed inverse correlation between pathogenic variant prevalence and age at diagnosis, with higher prevalence among individuals with early-onset tumors (18.4%) than average-onset (15.6%) or late-onset tumors (12.3%; <i>P<\/i> &lt; .001 for comparison).<\/p>\n<p>Testing identified high- or moderate-penetrance pathogenic variants in about one in 10 patients (9.7%). These variants accounted for a greater proportion of enrichment in early-onset cancers (12.4%) than average-onset (8.9%) or late-onset cancers (5.1%; <i>P<\/i> &lt; .001 for comparison).<\/p>\n<p>Had hereditary cancer testing been limited to patients diagnosed prior to age 50, about 4,600 pathogenic variant carriers \u2014 accounting for 72% of all people with variants \u2014 would have been missed.<\/p>\n<p>\u201cOur results confirm that early-onset cancers, regardless of type, are enriched for inherited genetic alterations,\u201d Stadler said. \u201cHowever, the vast majority of people don\u2019t get cancer before age 50. This much larger sample size, and the burden of hereditary risk among average- or late-onset cases, suggests that the age 50 cutoff probably is somewhat arbitrary.\u201d<\/p>\n<h2>Multiple benefits<\/h2>\n<p>Moving from conventional age-based criteria toward universal germline genetic testing could yield three distinct benefits, Stadler said.<\/p>\n<p>First, the findings have \u201ctherapeutic implications,\u201d Stadler said. For example, detection of <i>BRCA<\/i> variants can identify people with ovarian cancer or breast cancer who may benefit from treatment with PARP inhibitors.<\/p>\n<p>Second, genetic testing can inform decision-making during survivorship.<\/p>\n<p>A woman who survives breast cancer but does not know she harbors a <i>BRCA<\/i><i>1<\/i> variant may subsequently develop \u2014 and die of \u2014 ovarian cancer. In contrast, identification of a <i>BRCA1<\/i> mutation may prompt a person to undergo salpingo-oophorectomy \u2014 removal of the ovaries and fallopian tubes \u2014 to reduce risk for that secondary malignancy.<\/p>\n<p>\u201cMany more people are surviving cancer but, if they are at higher risk for a new malignancy, we need to know that so we can optimize early detection \u2014 and possibly prevention,\u201d Stadler said.<\/p>\n<p>Third, people found to harbor inherited variants often inform first-degree relatives, who typically have a 50% chance for carrying the same gene mutation.<\/p>\n<p>\u201cOne test doesn\u2019t just help the patient at hand,\u201d Stadler said. \u201cIf it leads to <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20260416\/virtual-tool-may-close-the-gap-in-cancer-genetic-testing-for-atrisk-relatives\" id=\"rId13\" target=\"_blank\">cascade testing<\/a> of at-risk relatives, it can have an impact on entire families.\u201d<\/p>\n<p>The researchers acknowledged study limitations. Its single-institution design and a cohort comprised primarily of Caucasian and Ashkenazi Jewish individuals could limit generalizability of the findings to more diverse populations, Stadler said, though she noted the results remained consistent among individuals of non-European ancestry. The cohort also included overrepresentation of people with pancreatic cancer and underrepresentation of people with <a rel=\"noopener noreferrer\" href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20260507\/stunned-half-of-older-adults-with-metastatic-lung-cancer-receive-no-systemic-treatment\" id=\"rId14\" target=\"_blank\">lung cancer<\/a>.<\/p>\n<p>Guidelines from professional societies such as National Comprehensive Cancer Network and ASCO \u2014 which greatly influence insurance coverage decisions \u2014 likely would need to be updated to endorse universal germline genetic testing for people with cancer for the approach to become broadly adopted, Stadler said.<\/p>\n<p>\u201cI certainly hope that happens,\u201d Stadler said. \u201cThe criteria we use to guide testing for some cancer types are so incredibly complex for healthcare professionals that the guideline itself becomes a barrier to testing. Hopefully our data will help move the needle toward universal germline genetic testing. With genetic testing being more accessible and less expensive than it used to be, we now need to get away from such strict criteria and put the infrastructure in place to identify and take care of these high-risk patients.\u201d<\/p>\n<h2>For more information:<\/h2>\n<p>      <b>Zsofia K. Stadler, MD,<\/b> can be reached at stadlerz@mskcc.org.<\/p>\n<div class=\"article__content--footer\">\n<div class=\"publisher-logo\">\n    <span>Published by:<\/span><br \/>\n    <img decoding=\"async\" src=\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hot.svg?la=en&amp;h=24&amp;w=141&amp;hash=2F86D471C8514C0E334E329AA799E8B4\" class=\"logo-img\" height=\"24\" alt=\"hemonc today logo\" width=\"141\"\/>\n  <\/div>\n<div class=\"sources-references-disclosures\">\n<h3>Sources\/Disclosures<\/h3>\n<h2> Source: <\/h2>\n<p class=\"citation\">&#13;<br \/>\n  <a href=\"https:\/\/aacrjournals.org\/cancerdiscovery\/article-abstract\/doi\/10.1158\/2159-8290.CD-26-0971\/788729\/Universal-Germline-Genetic-Testing-after-a\" id=\"rId11\" target=\"_blank\">Stadler ZK, et al. <i>Cancer Discov<\/i>. 2026;doi:10.1158\/2159-8290.CD-26-0971<\/a>.<\/p>\n<h2>Reference:<\/h2>\n<div class=\"disclosures\">\n<p>&#13;<br \/>\n        <strong> Disclosures: <\/strong>&#13;<br \/>\n        Stadler reports intellectual property rights in SOPHiA Genetics. She serves as editor in chief for <i>JCO Precision Oncology<\/i> and section editor for UpToDate. She also reports an immediate family member is cofounder, chief medical officer and president of Blue Gen Therapeutics Foundation and serves as a consultant in ophthalmology for Beacon Therapeutics, Eli Lilly &amp; Co. and Regeneron Pharmaceuticals Inc. Please see the study for all other authors\u2019 relevant financial disclosures. NIH and Memorial Sloan Kettering Cancer Center funded this study.&#13;\n      <\/p>\n<\/p><\/div>\n<\/div>\n<p><!-- Healio AI Widget --><\/p>\n<div class=\"healio-ai-component-inline\" data-no-ads=\"true\" data-module-track-category=\"Healio AI\" data-module-track-action=\"Click\" data-module-track-label=\"Access Healio Ai from component - News_AI Component - In-Content (all devices)\">\n<div class=\"healio-ai-content\">\n    <img decoding=\"async\" src=\"https:\/\/m3.healio.com\/~\/media\/images\/healio-ai\/healio-ai_logo.svg\" alt=\"Healio AI\" class=\"healio-ai-logo\"\/><\/p>\n<p><strong>Ask a clinical question<\/strong> and tap into <strong>Healio AI&#8217;s knowledge<\/strong> base.<\/p>\n<ul>&#13;<\/p>\n<li>PubMed, enrolling\/recruiting trials, guidelines<\/li>\n<p>&#13;<\/p>\n<li>Clinical Guidance, Healio CME, FDA news<\/li>\n<p>&#13;<\/p>\n<li>Healio&#8217;s exclusive daily news coverage of clinical data<\/li>\n<p>&#13;\n    <\/ul>\n<p>    <button class=\"healio-ai-button\" onclick=\"window.location.href=\" https:=\"\">Learn more<\/button>\n  <\/div>\n<\/div>\n<div class=\"email-alert-button-wrapper d-none\" data-component=\"EmailTopicAlert\" data-module=\"Subspecialty Email Topic Alerts Top\" data-manage-email-link=\"\/footer\/account-information\/my-account\/email-subscriptions-and-alerts#emailAlerts\">\n  <hidden data-setting-item=\"d265901d-6d37-49c7-a8f6-c7bf19a02509\"\/><br \/>\n  <hidden data-crm-source=\"Subspecialty Topic Alert\"\/><\/p>\n<div class=\"email-alert-button d-none\" data-topic-button=\"not-subscribed\">\n<p>&#13;<br \/>\n      <span data-module-track-action=\"Email Alerts TOP_Click_Healio News Article\" data-module-track-label=\"Email Alerts TOP_Healio News Article\">&#13;<br \/>\n        <i class=\"fas fa-plus-circle\"\/>&#13;<br \/>\n        Add topic to email alerts&#13;<br \/>\n      <\/span>&#13;\n    <\/p>\n<div class=\"email-alert-inner collapse u1ad81e56d32445208b911701f5d8da41\">\n<div class=\"email-alert-dialogue\">\n<p>&#13;<br \/>\n          Receive an email when new articles are posted on <span data-content=\"topic-title\"\/>&#13;\n        <\/p>\n<div class=\"d-none\" data-sign-up-type=\"unknown\">\n          Please provide your email address to receive an email when new articles are posted on <span data-content=\"topic-title\"\/>.<\/p><\/div>\n<\/p><\/div>\n<p>      <button type=\"button\" class=\"btn btn-primary\" data-loading-text=\"Loading &lt;i class=\" fa=\"\" fa-spinner=\"\" fa-spin=\"\">&#8220;&#13;<br \/>\n              data-action=&#8221;subscribe&#8221;&gt;&#13;<br \/>\n        Subscribe&#13;<br \/>\n      <\/button>\n    <\/div>\n<\/p><\/div>\n<div class=\"d-none\" data-topic-modal=\"failed\">    <strong>We were unable to process your request. Please try again later. If you continue to have this issue please contact <a href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20261116\/mailto:customerservice@slackinc.com\">customerservice@slackinc.com<\/a>.<\/strong>  <\/p>\n<p><button data-dismiss=\"modal\" class=\"btn btn-primary btn-lg btn-block\">Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.healio.com\/news\/hematology-oncology\/20261116\/universal-genetic-testing-in-cancer-replacing-arbitrary-age-cutoffs-is-right-move\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>November 18, 2026 4 min read &#13; &#13; &#13; Add topic to email alerts&#13; &#13; &#13; Receive an email when new articles are posted on &#13; Please provide your email address to receive an email when new articles are posted on . &#8220;&#13; data-action=&#8221;subscribe&#8221;&gt;&#13; Subscribe&#13; We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: A common age cutoff for germline genetic testing of solid tumors would have missed nearly three-quarters of people with pathogenic variants. The findings support universal testing for people with cancer. Use of a commonly used age-based cutoff for genetic testing among individuals with solid tumors resulted in a considerable proportion of inherited gene variants going undetected, according to study findings. An analysis of nearly 40,000 people with a variety of cancer types showed restricting germline genetic sequencing to those aged younger than 50 years would have missed nearly three-quarters of individuals who harbored pathogenic variants. &#13; &#13;&#13;&#13;&#13;&#13;&#13; &#13; &#13; &#13;&#13; Data derived from Stadler ZK, et al. Cancer Discov. 2026;doi:10.1158\/2159-8290.CD-26-0971.&#13; &#13; This equates to a \u201cmissed opportunity\u201d to obtain valuable information that could have profound implications for patients and their family members, according to lead author Zsofia K. Stadler, MD, chief of the clinical genetics service and gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center. Zsofia K. Stadler \u201cI have always thought that we should be moving toward universal testing for patients with cancer,\u201d Stadler told Healio. \u201cThese findings prove to us that this is the right move and should be the next step.\u201d \u2018Somewhat arbitrary\u2019 Prior research showed early-onset cancers tend to be more enriched for inherited genetic alterations. People with inherited genetic conditions linked to higher lifetime cancer risk \u2014 such as Lynch syndrome or hereditary breast ovarian cancer syndrome \u2014 also tend to be diagnosed at younger ages. Consequently, when genetic testing started \u201cin earnest\u201d about 25 years ago, age became part of the criteria to identify the population likely to derive the most benefit, Stadler said. \u201cOver the years, the pool of individuals eligible for testing for cancer risk genes has expanded tremendously, but criteria still vary by cancer type,\u201d she said. For example, genetic testing is recommended for everyone with ovarian cancer or pancreatic cancer. In other malignancies, testing decisions differ by age, family history, ancestry or tumor phenotype. Stadler and colleagues aimed to investigate whether an age 50 cutoff \u2014 which she described as a commonly used \u201cgatekeeper\u201d for genetic testing \u2014 remains relevant across cancer types, including those that typically present at older ages. The researchers performed germline sequencing on 39,184 unselected individuals with one of 32 solid tumor types, using the MSK-IMPACT assay to screen for 94 germline pathogenic variants. Investigators determined mean age at diagnosis for each cancer type, then used standard deviations to stratify people with each malignancy into three groups based on age at onset (average, early or late). One in six (16.3%) patients harbored at least one germline pathogenic variant. Results showed inverse correlation between pathogenic variant prevalence and age at diagnosis, with higher prevalence among individuals with early-onset tumors (18.4%) than average-onset (15.6%) or late-onset tumors (12.3%; P &lt; .001 for comparison). Testing identified high- or moderate-penetrance pathogenic variants in about one in 10 patients (9.7%). These variants accounted for a greater proportion of enrichment in early-onset cancers (12.4%) than average-onset (8.9%) or late-onset cancers (5.1%; P &lt; .001 for comparison). Had hereditary cancer testing been limited to patients diagnosed prior to age 50, about 4,600 pathogenic variant carriers \u2014 accounting for 72% of all people with variants \u2014 would have been missed. \u201cOur results confirm that early-onset cancers, regardless of type, are enriched for inherited genetic alterations,\u201d Stadler said. \u201cHowever, the vast majority of people don\u2019t get cancer before age 50. This much larger sample size, and the burden of hereditary risk among average- or late-onset cases, suggests that the age 50 cutoff probably is somewhat arbitrary.\u201d Multiple benefits Moving from conventional age-based criteria toward universal germline genetic testing could yield three distinct benefits, Stadler said. First, the findings have \u201ctherapeutic implications,\u201d Stadler said. For example, detection of BRCA variants can identify people with ovarian cancer or breast cancer who may benefit from treatment with PARP inhibitors. Second, genetic testing can inform decision-making during survivorship. A woman who survives breast cancer but does not know she harbors a BRCA1 variant may subsequently develop \u2014 and die of \u2014 ovarian cancer. In contrast, identification of a BRCA1 mutation may prompt a person to undergo salpingo-oophorectomy \u2014 removal of the ovaries and fallopian tubes \u2014 to reduce risk for that secondary malignancy. \u201cMany more people are surviving cancer but, if they are at higher risk for a new malignancy, we need to know that so we can optimize early detection \u2014 and possibly prevention,\u201d Stadler said. Third, people found to harbor inherited variants often inform first-degree relatives, who typically have a 50% chance for carrying the same gene mutation. \u201cOne test doesn\u2019t just help the patient at hand,\u201d Stadler said. \u201cIf it leads to cascade testing of at-risk relatives, it can have an impact on entire families.\u201d The researchers acknowledged study limitations. Its single-institution design and a cohort comprised primarily of Caucasian and Ashkenazi Jewish individuals could limit generalizability of the findings to more diverse populations, Stadler said, though she noted the results remained consistent among individuals of non-European ancestry. The cohort also included overrepresentation of people with pancreatic cancer and underrepresentation of people with lung cancer. Guidelines from professional societies such as National Comprehensive Cancer Network and ASCO \u2014 which greatly influence insurance coverage decisions \u2014 likely would need to be updated to endorse universal germline genetic testing for people with cancer for the approach to become broadly adopted, Stadler said. \u201cI certainly hope that happens,\u201d Stadler said. \u201cThe criteria we use to guide testing for some cancer types are so incredibly complex for healthcare professionals that the guideline itself becomes a barrier to<\/p>\n","protected":false},"author":1,"featured_media":4408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4407","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4407"}],"version-history":[{"count":0,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/posts\/4407\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=\/wp\/v2\/media\/4408"}],"wp:attachment":[{"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drsoniafawad.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}